For patients who harbor IDH1-mutant cholangiocarcinoma and who had progressed on previous therapy, the Phase III ClarIDHy trial showed a meaningful clinical benefit for the IDH1-Inhibitor ivosidenib compared with placebo. The gene discussed is IDH1; the disease is cholangiocarcinoma.